Trial Profile
A Prospective Multicenter Non-randomized Controlled Study of Sorafenib (Nexavar) Treatment in Patients With Hepatocellular Carcinoma With Microvascular Invasion After Radical Resection
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 16 Jun 2020
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 09 Feb 2020 Status changed from recruiting to discontinued.
- 16 Aug 2016 New trial record